Toansa

The consolidated profit in addition to revenue may also be adversely impacted due to certain expenses/ charges arising out of integration and remedial actions.

Ranbaxy loses Valcyte exclusivity: An analysis

Ranbaxy has first-to-file status, meaning eligibility for six months of generic sales exclusivity for both AstraZeneca's heartburn drug Nexium & Roche's antiviral drug Valcyte drugs. However, the final approvals for these drugs were delayed because of the compliance issues at Ranbaxy's plants.

Ranbaxy falls 4% post drug recall in US

Ranbaxy has recalled tablets of atorvastatin calcium, the generic name for Lipitor's active ingredient, after a pharmacist found a 20-milligram tablet in a sealed bottle marked for 10-milligram tablets, the US Food and Drug Administration (FDA) said.

Ranbaxy falls 2%, suspends API shipment from 2 plants

The drug major said that it is a voluntary decision as a precautionary measure to better to assess and review the processes and controls. It has also formed ‘quality & integrity committee'.

Ranbaxy suspends drug ingredients shipment from two plants

In January, the US Food and Drug Administration banned the Toansa plant, a key supplier of ingredients to the generic drugmaker's US factory, from sending its products to the United States due to manufacturing violations.

Key takeaways from Ranbaxy earnings commentary

In a conference call, the company, now owned by Japanese Daiichi Sankyo, said it was committed to resolving issues with the FDA, which has now banned imports from all four its plants in India.

Ranbaxy posts Q4 loss at Rs 159 cr on provision for Toansa

Total income from operations grew 6.7 percent to Rs 2,894 crore during the quarter as against Rs 2,711.2 crore in a year ago period.

Ranbaxy may post Q3 PAT at Rs 10 cr, guidance revision key

Analysts are worried about the guidance (Rs 13,000-13,500 crore - with no first-to-file included) after the US Food and Drug Administration (USFDA) banned manufacturing and distributing active pharmaceutical ingredients from its Toansa facility. Toansa was the fourth plant that was banned by USFDA after Mohali, Dewas and Poanta.

Daiichi pledges bold action on Ranbaxy production problems

RANBAXY-BAN-DAIICHISANKYO:Daiichi Sankyo pledges bold action on Ranbaxy production problems

Ranbaxy sheds 9%; brokerages downgrade, doctors wary

UBS maintains sell rating and reduced target price to Rs 300 from 500. Stating that downside risks remain, UBS is concerned that USFDA action removes US as a potential earnings driver and may take three to five years for issues to get resolved.

Weekly wrap: Late global sell-off wipes most gains; Rupee, RBI hold key

Bank and IT shares gained during the week, while those from capital goods, metal, auto, power and oil & gas shares finished lower.

Analysts advise how to trade Ranbaxy, say EBITDA may fall

Toansa is the fourth unit of the company which is banned and added to consent decree. With this, all of the company's India-based plants supplying to US are banned. Its Ohm Laboratories, the only plant which has USFDA approval, manufactures drugs using API from Toansa.

Wipro, Reliance gain 1%; Sensex, Nifty under pressure

Ranbaxy tanks on USFDA blow. The US FDA bans Ranbaxy's Toansa API plant and added it to consent decree.

Pick Ranbaxy below Rs 300; see biz value: Religare

Arvind Bothra, VP of Religare Enterprises says even with an average multiple of 7 to 8 times sales on the domestic business, the value will be higher than the current market cap.

Ranbaxy ban: Outsourcing an option, negative EBIDTA seen

Ranbaxy‘s Toansa plant supplies 70 percent of US-based Ohm Laboratories‘ Active Pharmaceutical Ingredients (API) requirement. This in turn means the company will soon have to go in for outsourcing, incurring a huge costs.

Ranbaxy plunges 20% on USFDA ban on Toansa API plant

Toansa is the fourth unit of the company that is banned and added to consent decree. With this, all of the company's India-based plants supplying to US are banned.

Ranbaxy may take long to recover from USFDA woes: Angel

Ranbaxy has received a form 483 with certain observations from the USFDA on its Toansa bulk drug plant in Punjab.

Ranbaxy Toansa plant gets Form 483, stock down 8%

Ranbaxy has said that it is assessing the observations and will respond to the USFDA at the earliest. This matter is critical for Ranbaxy since 70-75 percent of the company‘s manufactured active pharmaceutical ingredients (APIs) are from there, reports CNBC-TV18.